Patents Issued in March 18, 2008
-
Patent number: 7344685Abstract: A sealed multi-chambered bag, that is a flexible container, is made of dielectric material and contains two electrode plates (preferably screen plates) that are separated by an internal wall of the bag. Materials to be sterilized are placed between one or the other or both of the electrode plates and the interior wall. The interior wall allows the plates to be contained within the bag without the risk of damaging high voltage discharges occurring between plates optimal ozone production occurs in the bag immediately adjacent to where the materials to be sterilized are located. The bag is placed within a chamber containing an aperture which is connected to the intake of a pump. A conductor connects each electrode plate to an opposed terminal of a high tension transformer.Type: GrantFiled: January 17, 2004Date of Patent: March 18, 2008Inventor: James F. McNulty
-
Patent number: 7344686Abstract: Fuel is desulfurized with a rapid cycle desulfurization-regeneration method and apparatus. Regeneratable mass separating agents, including metals supported on high surface area materials, are used in a plurality of beds that are rotated into, through, and out of a desulfurization series and a regeneration series by valves and plumbing, which can include a rotary valve apparatus.Type: GrantFiled: October 7, 2004Date of Patent: March 18, 2008Assignee: Mesoscopic Devices, Inc.Inventors: Joseph C. Poshusta, Jerry L. Martin
-
Patent number: 7344687Abstract: A fuel cell power plant comprises a fuel reforming system (1). The fuel reforming system (1) comprises a vaporizer (7) which vaporizes liquid fuel and supplies fuel vapor to a reformer (9). The vaporizer (7) heats injected fuel so as to vaporize it by a heating elements (7A), and supplies it to the reformer (9) via a fuel vapor supply passage (32) comprising a first valve (17). In a standby mode of the vaporizer (7) when the first valve (17) is closed, surplus fuel and heat energy in the standby state are recovered by providing a recovery passage (19, 20) which recovers fuel in the vicinity of the heating elements (7A) to the fuel tank (6) without allowing it to flowing into the vapor supply passage (32).Type: GrantFiled: April 24, 2003Date of Patent: March 18, 2008Assignee: Nissan Motor Co., Ltd.Inventors: Takashi Oi, Yasukazu Iwasaki
-
Patent number: 7344688Abstract: The invention relates to a process for treating alkali metals such as sodium charged with tritium or components contaminated with alkali metals such as sodium charged with tritium, in which the alkali metal is reacted with liquid water or water vapor, so as to obtain hydrogen and tritiated hydrogen, characterized in that the hydrogen and the tritiated hydrogen are subjected, in a recombiner (2) to a treatment of catalytic recombination by the addition of oxygen so as to obtain water and tritiated water, and in that the water and the tritiated water are treated so that they are not discharged into the environment. The invention also relates to a plant for carrying out the process.Type: GrantFiled: August 18, 2004Date of Patent: March 18, 2008Assignee: Framatome ANPInventors: Olivier Carra, Yves Demoisy
-
Patent number: 7344689Abstract: A silicon wafer for an IGBT is produced by forming an ingot having an interstitial oxygen concentration [Oi] of not more than 7.0×1017 atoms/cm3 by the Czochralski method; doping phosphorus in the ingot by neutron beam irradiation to the ingot; slicing a wafer from the ingot; performing annealing of the wafer in an oxidizing atmosphere containing at least oxygen at a temperature satisfying a predetermined formula; and forming a polysilicon layer or a strained layer on one side of the wafer.Type: GrantFiled: June 7, 2006Date of Patent: March 18, 2008Assignee: Sumco CorporationInventors: Shigeru Umeno, Yasuhiro Oura, Koji Kato
-
Patent number: 7344690Abstract: In one aspect, the invention provides a hydrogen storage composition having a hydrogenated state and a dehydrogenated state. In the hydrogenated state, such composition comprises an amide and a hydride. In a dehydrogenated state, the composition comprises an imide.Type: GrantFiled: April 15, 2004Date of Patent: March 18, 2008Assignee: General Motors CorporationInventors: Gregory P Meisner, Frederick E Pinkerton, Martin S Meyer, Michael P Balogh, Matthew D Kundrat
-
Patent number: 7344691Abstract: A system and method for manipulation of nanotubes using an organic material that is presented to the nanotubes. Exemplary types of manipulation include cutting nanotubes into shortened nanotubes, dispersing nanotubes, enabling dissolution of nanotubes, and noncovalently functionalizing nanotubes. The organic material used in manipulating nanotubes preferably comprises a solid organic material, soluble organic material, and/or an organic material that acts as a dispersing reagent for dispersing nanotubes. In a preferred embodiment, the organic material used for manipulating nanotubes comprises cyclodextrin.Type: GrantFiled: December 10, 2003Date of Patent: March 18, 2008Assignee: Zyvek Performance Materials, LLCInventors: Jian Chen, Mark J. Dyer
-
Patent number: 7344692Abstract: A process for the regeneration of sulfuric acid contaminated with hydrocarbons and water to produce pure concentration acid comprising: contacting sulfuric acid contaminated with hydrocarbons and water with oxygen and elemental sulfur in the presence of a vanadium containing catalyst in a reaction zone, maintaining at least a portion of the acid in the liquid phase, converting hydrocarbon to carbon oxides and water, and converting sulfur and sulfurdioxide to sulfurtrioxide, separating the reactor effluent into a vapor stream and a liquid stream and cooling and partially condensing of the vapor stream to concentrate clean acid.Type: GrantFiled: December 14, 2005Date of Patent: March 18, 2008Assignee: Catalytic Distillation TechnologiesInventors: Lawrence A. Smith, Jr., Abraham P. Gelbein
-
Patent number: 7344693Abstract: There are provided: (I) a process for producing zirconia powder, which comprises the step of calcining a zirconium salt in an atmosphere containing hydrogen chloride, and (II) a process for producing zirconia powder, which comprises the steps of: (1) pre-calcining a zirconium salt to obtain a pre-calcined product, and (2) calcining the pre-calcined product in an atmosphere containing hydrogen chloride.Type: GrantFiled: May 8, 2002Date of Patent: March 18, 2008Assignee: Sumitomo Chemical Company, LimitedInventors: Yoshio Uchida, Ichiro Tanaka
-
Patent number: 7344694Abstract: A series of crystalline alumino-silicate zeolites identified as UZM-12 have been synthesized. These UZM-12 compositions have the ERI topology, a Si/Al>5.5 and can be prepared as nanocrystallites having an average particle size of about 15 to about 50 nanometers and a spheroidal morphology. The UZM-12 composition can be treated to remove at least a fraction of the framework aluminum atoms thereby providing zeolites with a Si/Al>5.75 and identified as UZM-12HS. Both the UZM-12 and UZM-12HS can catalyze various hydrocarbon conversion processes.Type: GrantFiled: October 6, 2004Date of Patent: March 18, 2008Assignee: UOP LLCInventors: Mark A. Miller, Gregory J. Lewis, Jana L. Gisselquist, Jaime G. Moscoso, R. Lyle Patton
-
Patent number: 7344695Abstract: A novel method of forming ZSM-5 comprises reacting calcined kaolin microspheres with silicate and a seed solution used for forming zeolite Y under conditions of pH, temperature, and time to yield ZSM-5 crystals formed in-situ on said calcined kaolin microspheres. The reaction medium does not contain any organic templates or ZSM-5 seeding crystals.Type: GrantFiled: March 14, 2005Date of Patent: March 18, 2008Assignee: Engelhard CorporationInventors: Mingting Xu, John Macaoay
-
Patent number: 7344696Abstract: The invention relates to a porous crystalline material (ITQ-24), the preparation method thereof and the use of same in the catalytic conversion of organic compounds. More specifically, the invention relates to a synthetic porous crystalline material which is characterised in that it is formed by tetrahedrally coordinated atoms which are interconnected by means of oxygens. Said material, which comprises a unit cell containing 56 tetrahedrally coordinated atoms, is known as ITQ-24. Moreover, in the calcined anhydrous state, the material has chemical formula nM1/pXO2: YO2, wherein: X is at least one trivalent element, Y is at least one tetravalent element, n is between 0 and 0.2 and M is at least one charge compensation cation in oxidation state p.Type: GrantFiled: August 9, 2005Date of Patent: March 18, 2008Assignees: Consejo Superior de Investigaciones Cientificas, Universidad Politecnica de ValenciaInventors: Avelino Corma Canós, Rafael Castañeda Sánchez, Vicente Fornés Seguí, Fernando Rey García
-
Patent number: 7344697Abstract: The invention relates to a microporous crystalline zeolite material, zeolite ITQ-28, the production method thereof and the use of same. More specifically, the invention relates to a microporous crystalline zeolite material, ITQ-28, which, in the calcined state and in the absence of defects in the crystalline lattice thereof, manifested by the presence of silanols, is characterised by having empirical formula x (M1/nXO2): y YO2: SiO2, wherein: M is selected from H+, at least one inorganic cation with charge +n, preferably alkalines or alkaline earths, and a mixture of both; X is at least one chemical element in oxidation state +3, preferably Al, Ga, B, Fe, Cr or mixtures thereof; Y is at least a chemical element in oxidation state +4, which is different from Si, preferably Ge, Ti, Sn, V or mixtures of same; x has a value of between 0 and 0.2 inclusive; and y has a value of between 0 and 0.1 inclusive.Type: GrantFiled: March 29, 2006Date of Patent: March 18, 2008Assignees: Consejo Superior de Investigaciones Cientificas, Universidad Politecnica de ValenciaInventors: Avelino Corma Canós, María José Sabater Picot, Susana Valencia Valencia
-
Patent number: 7344698Abstract: Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for ?v?3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, radionuclides, or other imaging agents.Type: GrantFiled: December 16, 2005Date of Patent: March 18, 2008Assignees: Barnes-Jewish Hospital, Bristol-Myers Squibb Medical Imaging, Inc.Inventors: Gregory M. Lanza, Samuel A. Wickline, Tom Harris
-
Patent number: 7344699Abstract: A drug conjugate comprising a targeting agent and an anti-cancer agent, wherein said targeting agent comprises an erythropoietin receptor ligand, is described. The drug conjugate can be used in methods of treating cancer. Also described are methods of treating cancer using the conjugate, methods of diagnosis, methods of imaging and pharmaceutical compositions.Type: GrantFiled: May 21, 2003Date of Patent: March 18, 2008Assignee: The Queen's University of BelfastInventors: Terence Lappin, John Mann, Michael McManus, Perry Maxwell
-
Patent number: 7344700Abstract: Provided is a class of radiolabeled androgen receptor targeting agents (ARTA), useful for prostate cancer imaging and in treating or preventing prostate cancer. The agents define a new-subclass of radiolabeled compounds, which are selective androgen receptor modulators (SARM), which demonstrate antiandrogenic activity of a nonsteroidal ligand for the androgen receptor, and/or which bind irreversibly to the androgen receptor. The present invention further provides methods for a) imaging of cancer in a subject, b) imaging an androgen receptor-containing tissue in a subject, c) in-vivo imaging in a subject, d) treating a subject suffering from prostate cancer, e) delaying the progression of prostate cancer in a subject suffering from prostate cancer, f) preventing the recurrence of prostate cancer in a subject suffering from prostate cancer, and g) treating the recurrence of prostate cancer in a subject suffering from prostate cancer, which comprise using the radiolabeled compounds of the present invention.Type: GrantFiled: February 24, 2003Date of Patent: March 18, 2008Assignee: University of Tennessee Research CorporationInventors: James T. Dalton, Duane D. Miller, Leonid I. Kirkovsky, Arnab Mukherjee
-
Patent number: 7344701Abstract: The invention provides a novel class of xanthene dyes, some of which are functionalized to allow their coupling to conjugation partners of interest, e.g. biomolecules, drugs, toxins and the like. Also provided are conjugates of the dyes, methods of preparing and using the dyes and their conjugates and kits including the dyes and their conjugates.Type: GrantFiled: April 13, 2004Date of Patent: March 18, 2008Assignee: Biosearch Technologies, Inc.Inventors: Mark Reddington, Matt Lyttle
-
Patent number: 7344702Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.Type: GrantFiled: February 10, 2005Date of Patent: March 18, 2008Assignee: Bristol-Myers Squibb Pharma CompanyInventors: David S. Casebier, Simon P. Robinson, Ajay Purohit, Heike S. Radeke, Michael T. Azure, Douglas D. Dischino
-
Patent number: 7344703Abstract: Novel mycobacterial sulfation pathway proteins and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting growth and/or virulence of a pathogenic mycobacterium, and methods of treating disease conditions associated with a pathogenic mycobacterium, particularly by administering an inhibitor of a mycobacterial sulfation pathway protein. The present invention further provides genetically modified mycobacteria having a defect in a sulfation pathway enzyme gene; and immunogenic compositions that include such genetically modified mycobacteria.Type: GrantFiled: September 1, 2005Date of Patent: March 18, 2008Assignee: The Regents of the University of CaliforniaInventors: Carolyn R. Bertozzi, Spencer J. Williams, Joseph D. Mougous
-
Patent number: 7344704Abstract: The invention relates to the use of perfluoroalkyl-containing metal complexes that have a critical micelle formation concentration <10?3 mol/l, a hydrodynamic micelle diameter (2 Rh)>1 nm and a proton relaxivity in plasma (R1)>10 l/mmol·s as contrast media in MR imaging for visualization of intravascular thrombi.Type: GrantFiled: July 10, 2003Date of Patent: March 18, 2008Assignee: Schering AGInventors: Bernd Misselwitz, Johannes Platzek, Yoko Kawata, Hanns-Joachim Weinmann, Takashi Yokawa, Ulrich Niedballa
-
Patent number: 7344705Abstract: Low density microspheres, methods for preparing same, and use of same as contrast agents are described. The microspheres have a void which contains a gas or the vapor of a volatile liquid selected from the group consisting of aliphatic hydrocarbons, chlorofluorocarbons, tetraalkyl silanes and perfluorocarbons.Type: GrantFiled: October 18, 2005Date of Patent: March 18, 2008Assignee: Bristol-Myers Squibb Medical Imaging, Inc.Inventor: Evan C. Unger
-
Patent number: 7344706Abstract: UV absorber compositions are described, comprising (a) from 1 to 99% by weight of a hydroxyphenyltriazine compound of formula (I) wherein R1, R2 and R3 are each independently of the others C1-C18alkyl; C2-C10,alkenyl; or phenyl-C1-C4 alkyl; R4 is hydrogen; or C1-C5alkyl; and (b) from 99 to 1% by weight of a further UV absorber selected from the group of (b) hydroxyphenyltriazines that are different from component (a), (b2) benzotriazoles, (b3) dibenzoylmethane derivatives and (b4) camphor derivatives.Type: GrantFiled: March 4, 2003Date of Patent: March 18, 2008Assignee: Ciba Specialty Chemicals Corp.Inventors: Jürg Haase, Thomas Ehlis, Elek Borsos, Dietmar Hüglin, Bernd Herzog
-
Patent number: 7344707Abstract: A low combustion aerosol antiperspirant product in a plastic package having a reduced fire hazard classification. The low combustion product has a chemical heat of combustion equal or less than about 30 kJ/g. The plastic package is made of plastic. The plastic package is capable of containing and dispensing the low combustion product. The plastic package is stable when containing the product and together they have a fire hazard classification of 1 or 2. The low combustion aerosol product may be an anhydrous antiperspirant product.Type: GrantFiled: May 15, 2002Date of Patent: March 18, 2008Assignee: The Procter & Gamble CompanyInventors: Scott Edward Smith, David Frederick Swaile
-
Patent number: 7344708Abstract: The present invention relates to a series of novel silicone polyesters which are prepared by crosslinking a dimethicone copolyol having at least 4 hydroxyl groups with a dimer acid. The ratio of acid groups to hydroxyl groups ranges from 0.7 to 1.4 so that a significant number of groups are reacted and a significant number of crosslink groups are achieved.Type: GrantFiled: November 17, 2004Date of Patent: March 18, 2008Assignee: Zenitech LLCInventors: Carter LaVay, Anthony J. O'Lenick, Jr.
-
Patent number: 7344709Abstract: The present invention relates to the use of recombinant IFN-beta for the production of a medicament for the treatment of HCV infection by subcutaneous administration to patients of Asian race, which failed to respond to a previous treatment with interferon-alpha, is herein reported. According to a preferred embodiment of the invention, this treatment can be better and further focused to those patients which after at least 4 weeks of initial treatment with IFN-beta show HCV RNA clearance.Type: GrantFiled: May 28, 2003Date of Patent: March 18, 2008Assignee: Laboratories Serono SAInventors: Ian Parsons, Theodor Wee Tit Gin, Birgit Maschek
-
Patent number: 7344710Abstract: Current chemotherapeutic approaches for cancer are in part limited by the inability of drugs to destroy neoplastic cells within poorly vascularized compartments of tumors. We have here systematically assessed anaerobic bacteria for their capacity to grow expansively within avascutar compartments of transplanted tumors. Among 26 different strains tested, one (Clostridium novyi) appeared particularly promising. We created a strain of C. novyi devoid of its lethal toxin (C. novyi-NT) and showed that intravenously injected C. novyi-NT spores germinated within the avascular regions of tumors in mice and destroyed surrounding viable tumor cells. When C. novyi-NT spores were administered together with conventional chemotherapeutic drugs, extensive hemorrhagic necrosis of tumors often developed within 24 hours, resulting in significant and prolonged anti-tumor effects. This strategy, called combination bacteriolytic therapy (COBALT), has the potential to add a valuablle dimension to the treatment of cancer.Type: GrantFiled: November 21, 2002Date of Patent: March 18, 2008Assignee: The Johns Hopkins UniversityInventors: Long Dang, Kenneth W. Kinzler, Bert Vogelstein
-
Patent number: 7344711Abstract: This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs.Type: GrantFiled: March 25, 2003Date of Patent: March 18, 2008Assignee: Oncolytics Biotech Inc.Inventors: Ramon Alemany Bonastre, Manel Maria Piqueras
-
Patent number: 7344712Abstract: A method for providing a urinary tract tissue graft composition includes providing a segment of small intestinal submucosa and positioning the segment of small intestinal submucosa in a tissue culture frame such that the segment of small intestinal submucosa is suspended and held in a taut position by the tissue culture frame. At least one multipotent cell type is isolated from a tissue specimen of a subject and cultured, and then seeded upon a surface of the segment of small intestinal submucosa, thereby forming a urinary tract tissue graft. Methods for repairing a damaged urinary tract tissue of a subject are also disclosed.Type: GrantFiled: July 31, 2003Date of Patent: March 18, 2008Assignee: The Board of Regent of the University of OklahomaInventors: Bradley Kropp, Earl Y. Cheng, Yuan Yuan Zhang, Hsueh-Kung Lin, Rick Cowan
-
Patent number: 7344713Abstract: A method for the decrease of fat absorption in a mammal, wherein the animal is orally fed an antibody produced against lipase, an enzyme which is required for fat absorption.Type: GrantFiled: July 7, 1997Date of Patent: March 18, 2008Inventor: Julio L. Pimentel
-
Patent number: 7344714Abstract: The present invention is related to a method for producing motif-specific, context-independent antibodies which are specific to at least one modified amino acid residue in the context of variable surrounding amino acid or peptide sequences. The method is particularly useful in producing antibodies which recognize phosphorylated serine, threonine, and tyrosine, or acetylated lysine, as well as other modified amino acids-containing motifs of one or more amino acids.Type: GrantFiled: May 7, 2002Date of Patent: March 18, 2008Assignee: Cell Signaling Technology, IncInventors: Michael J. Comb, Yi Tan
-
Patent number: 7344715Abstract: The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody.Type: GrantFiled: July 5, 2002Date of Patent: March 18, 2008Assignee: Immune System Therapeutics LtdInventors: Robert Lindsay Raison, Rosanne Dorothy Dunn, Boon Hwa Andre Choo
-
Patent number: 7344716Abstract: The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.Type: GrantFiled: June 6, 2003Date of Patent: March 18, 2008Assignee: DePuy Spine, Inc.Inventors: Thomas M. DiMauro, Hassan Serhan, Mohamed Attawia
-
Patent number: 7344717Abstract: A novel use of the known protein Erythropoietin (EPO) and/or a derivative and/or a fragment thereof is disclosed. EPO is used as a pharmaceutical for the treatment of chronic inflammations. A particularly beneficial result is seen in patients suffering from rheumatoid arthritis (RA). Significant effects are seen in clinical variables such as morning stiffness, swollen joints, and the like.Type: GrantFiled: October 26, 1995Date of Patent: March 18, 2008Assignee: Roche Diagnostics GmbHInventor: Anthonius Josef Swaak
-
Patent number: 7344718Abstract: A method of protecting an animal from infections with pathogens originating from Yersinia comprising administering an isolated or recombinant YscF protein to the animal is disclosed. The isolated or recombinant YscF protein may be administered as a vaccine. An isolated or recombinant YscF protein capable of conferring protection to an animal against a pathogen of a Yersinia origin is further disclosed. Nucleic acid molecules encoding the isolated or recombinant YscF protein are also disclosed. In other embodiments, antibodies generated against the isolated or recombinant YscF protein capable of conferring protection to an animal against a pathogen or a Yersinia origin and uses of the antibodies are described.Type: GrantFiled: July 18, 2003Date of Patent: March 18, 2008Assignee: University of North DakotaInventors: Matthew L. Nilles, Jyl S. Matson
-
Patent number: 7344719Abstract: The present invention is directed to the cloning, sequencing and expression of homologous immunoreactive 28-kDa protein genes, p28-1, -2, -3, -5, -6, -7, -9, from a polymorphic multiple gene family of Ehrlichia canis. Further disclosed is a multigene locus encoding all nine homologous 28-kDa protein genes of Ehrlichia canis. Recombinant Ehrlichia canis 28-kDa proteins react with convalescent phase antiserum from an E. canis-infected dog, and may be useful in the development of vaccines and serodiagnostics that are particularly effective for disease prevention and serodiagnosis.Type: GrantFiled: December 9, 2003Date of Patent: March 18, 2008Assignee: Research Development FoundationInventors: David H. Walker, Xue-Jie Yu, Jere W. McBride
-
Patent number: 7344720Abstract: The present invention relates to a pharmaceutical composition comprising at least one vaccine antigen, which also comprises at least one phosphoric ester derivative of phosphatidylcholine having the structure: in which: R1 is a lower alkyl, R2 and R3 are identical or different, and can each represent linear hydrocarbon-based chains having from 13 to 21 carbon atoms.Type: GrantFiled: November 15, 2004Date of Patent: March 18, 2008Assignee: Sanofi Pasteur SAInventor: Jean Haensler
-
Patent number: 7344721Abstract: This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His-Thr-Phe-Met-Gy-Val-Val-Ser-Leu-Gly (SEQ ID NO: 3) and correlates to amino acid no. 300-309 of bovine fetuin, referred to herein as Fetuin Peptide Fragment (FPF 300-09). FPF 300-09 strongly induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the FPF 300-09 is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. FPF 300-09 has a LD50 of 0.3-0.4 ?M, while the LD50 for zinc-charged fetuin is 3-10 ?M.Type: GrantFiled: July 8, 2005Date of Patent: March 18, 2008Inventor: David Tsai
-
Patent number: 7344722Abstract: The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were found between the sequences identified herein and the previously published sequences for cold-adapted A/Ann Arbor/6/60 genes. The cold-adapted live influenza virus of the present invention can be reassorted with a variety of epidemic wild type influenza viruses and used to produce vaccines to prophylactically and therapeutically treat influenza.Type: GrantFiled: December 14, 1995Date of Patent: March 18, 2008Assignee: The Regents of the University of MichiganInventors: Hunein F. Maassab, Martha Louise Herlocher
-
Patent number: 7344723Abstract: A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV RNA in cell culture. This self-replicating polynucleotide molecule contains, contrary to all previous reports, a 5?-NTR that can be either an A as an alternative to the G already disclosed and therefore provides an alternative to existing systems comprising a self-replicating HCV RNA molecule. The G-->A mutation gives rise to HCV RNA molecules that, in conjunction with mutations in the HCV non-structural region, such as the G(2042)C/R mutations, possess greater efficiency of transduction and/or replication. These RNA molecules when transfected in a cell line are useful for evaluating potential inhibitors of HCV replication.Type: GrantFiled: February 27, 2004Date of Patent: March 18, 2008Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: George Kukolj, Arnim Pause
-
Patent number: 7344724Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.Type: GrantFiled: June 21, 2004Date of Patent: March 18, 2008Assignees: Board of Regents, The University of Texas System, Wyeth Holdings CorporationInventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
-
Patent number: 7344725Abstract: The use of inorganic nanoparticles to stabilize aqueous hydrogen peroxide solutions is described. The preferred nanoparticles are formed from clays. The use of nanoparticles formed from synthetic smectite clays is particularly preferred. The stabilized hydrogen peroxide solutions may be utilized for various purposes, but are particularly useful as contact lens disinfecting solutions.Type: GrantFiled: November 16, 2004Date of Patent: March 18, 2008Assignee: Alcon, Inc.Inventors: Howard Allen Ketelson, Nathaniel D. McQueen
-
Patent number: 7344726Abstract: In a process for the preparation of an article having a contact biocidal property, there is provided a polymer solution which contains atomic/metallic silver in suspension or complexed with the polymer and/or which contains a silver compound in solution, in suspension or complexed with the polymer. This polymer solution is applied to a substrate by impregnation or surface deposition, thus coating the substrate. Alternatively, it is possible to convert the polymer solution to a fibre, film, powder or foam, effectively forming the article from the polymer solution instead of coating an existing article. In either case, any silver compound present is reduced to atomic/metallic silver, and the resultant article is dried. Chitosan is preferably used as the polymer, although poly(vinyl alcohol) and sodium alginate can also be used. The polymer may be cross-linked at a suitable point in the process to insolubilize it.Type: GrantFiled: August 17, 2001Date of Patent: March 18, 2008Assignee: Chitoproducts LimitedInventors: Alan Taylor, George Andrew Francis Roberts, Frances Ann Wood
-
Patent number: 7344727Abstract: Animals have been domesticated and kept as a source of milk for tens of thousands of years, When humans keep animals for their ability to produce milk, the animals are usually kept in confined spaces. As a result of this confinement the animals are exposed to high levels of urine and fecal matter which originated with the animals which are being kept. This exposure contaminates the animal and in particular the udder and teats of the animal, with bacteria. In the milking process this bacteria can further contaminate the milk which is destine for human consumption. The bacteria can further cause mastitis in the bovine. The above set forth problems are eliminated in the subject invention wherein the udder and teat areas of the bovine are sanitized with a solution of trichloromelamine.Type: GrantFiled: December 10, 2003Date of Patent: March 18, 2008Assignee: H&S Chemical Company, Inc.Inventors: David J. Schneider, Charles A. Schneider
-
Patent number: 7344728Abstract: An insect repellent composition that includes a blend of either all natural oils or synthetic ingredients, a sunscreen vitamin F, volatile silicones to extend the effective repellent life of the spray and a film forming polymer to resist water wash off. The natural oils and extracts can include citronella and orange and the synthetics can include D-limonene and phtalic acid.Type: GrantFiled: January 30, 2003Date of Patent: March 18, 2008Inventor: Stephen C. Perry
-
Patent number: 7344729Abstract: A combustible pesticidal product is disclosed which comprises a structural element formed from a cardboard having a thickness of at least 0.75 mm, a density of 450-850 kgm3 and consisting of 1 or more plies, the cardboard including: an alkali or alkaline earth metal nitrate or nitrite in an amount of from 0 to 1.83% w/w, or an alkali or alkaline earth carbonate or bicarbonate in an amount of from 0.02 to 7.0% w/w; one or more mineral silicates in an amount of from 0.01 to 8.0% w/w; a phosphate in an amount of from 0.01 to 0.40% w/w and selected from the group consisting of diammonium phosphate, monoammonium phosphate, triammonium phosphate and mixtures thereof; a boron compound in an amount of from 0.001 to 0.Type: GrantFiled: August 21, 2001Date of Patent: March 18, 2008Assignee: Reckitt Benckiser (Australia) Pty LimitedInventors: Bruce Graham Kemmis, Rosita Junus
-
Patent number: 7344730Abstract: The present invention relates to soil-applied CR granules obtainable by applying an active-ingredient-comprising coating to a solid carrier in a fluidized bed, to a process for the preparation of these soil-applied granules, and to a method for controlling phytopathogenic fungi, undesired vegetation, undesired attack by insects and/or for regulating the growth of plants using the soil-applied CR granules according to the invention.Type: GrantFiled: July 28, 1999Date of Patent: March 18, 2008Assignee: BASF SEInventors: Reinhold Stadler, Reiner Kober, Karl-Heinrich Schneider, Reinhold Saur, Herbert Bayer, Karl Kolter, Michael Seufert
-
Patent number: 7344731Abstract: A copolymer useful as a rigid gas permeable contact lens material is the polymerization product of a monomeric mixture comprising a polysiloxane-containing urethane or urea prepolymer endcapped with polymerizable ethylenically unsaturated radicals.Type: GrantFiled: June 6, 2005Date of Patent: March 18, 2008Assignee: Bausch & Lomb IncorporatedInventors: Yu-Chin Lai, James A. Bonafini, Jr.
-
Patent number: 7344732Abstract: A tampon adapted to deliver a therapeutic agent, the tampon including a tampon body that is manufactured at a first manufacturing facility; and a dosage form coupled to the body, wherein the dosage form includes a formulation including a therapeutic agent, and wherein the dosage form is manufactured at a second manufacturing facility. Also, a method for producing a medicated tampon including manufacturing a tampon body at a first manufacturing facility; manufacturing a dosage form at a second manufacturing facility, wherein the dosage form includes a formulation including a therapeutic agent; and coupling the dosage form to the tampon body.Type: GrantFiled: December 31, 2002Date of Patent: March 18, 2008Assignee: Kimberly-Clark Worldwide, Inc.Inventor: Steven Craig Gehling
-
Patent number: 7344733Abstract: The invention relates to an active-ingredient-containing, matrix-controlled transdermal therapeutic system for the use of pramipexole, ropinirole, pharmaceutically acceptable salts thereof or pharmaceutically acceptable derivatives thereof.Type: GrantFiled: July 26, 2002Date of Patent: March 18, 2008Assignee: Hexal AGInventors: Cornelia Beier, Martina Wilhelm
-
Patent number: 7344734Abstract: The invention relates to a powder formulation for administration by inhalation comprising an active substance and a pharmaceutically acceptable excipient, which composition has the form of a physical mixture and comprises from 5 to 25 wt. % of the excipient, and wherein the active substance has a particle size distribution of from 0.5 to 10 ?m, and wherein the excipient has a particle size distribution of from 15 to 500 ?m.Type: GrantFiled: August 19, 2002Date of Patent: March 18, 2008Assignee: Rijksuniversiteit GroningenInventors: Hendrikus Gerardus M. Heijerman, Petrus Paulus H. Le Brun, Henderik Willem Frijlink, Anne Haaije de Boer